A Nevada federal court recently ruled in favor of Ferring Pharmaceuticals, Inc. in an abbreviated new drug application (ANDA) patent infringement trial. Following a bench trial, the court found “Ferring’s patents were valid and infringed by both Watson and Apotex.” In a statement, Ferring president and chief operating officer, Aaron Graff said, “Ferring has been 100 percent committed to protecting our intellectual property, and we are pleased by the outcome.” Finnegan represented Ferring in this matter.
Media Mention
Ferring Pharmaceuticals Tells Federal Circuit Generics Companies Infringed Lysteda IP
June 10, 2014
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Media Mention
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.